Klinische Studien und weitere klinische Arbeiten:

Arend WP, van den Berg WB, Bresnihan B, Watt I, Genant HK. Can novel therapies preserve greater function with rheumatoid arthritis? Targeted IL-1 inhibition. Semin Arthritis Rheum. 2001;30(suppl 2).

Arend WP. Cytokines and cellular interactions in inflammatory synovitis (commentary). J Clin Invest. 2001;107:1081-1082.

Arend WP. Cytokine imbalance pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. Semin Arthritis Rheum. 2001;30:1-6.

Bresnihan B, Cunnane G. Interleukin-1 receptor antagonist. Rheum Dis Clin North Am. 1998;24:615-628.

Bresnihan B, Alvaro-Garcia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41:2196-2204.

Bresnihan B. Treatment of rheumatoid arthritis with interleukin-1 receptor antagonist. Ann Rheum Dis. 1999;58(suppl):196-198.

Bresnihan B. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 2001;30:17-20.

Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M, Group I. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum. 1996;39:1092-1101.

Cunnane G, Cassidy N, Madigan A, Murphy E, Fitzgerald O, Bresnihan B. The effects of treatment with interleukin-1 receptor antagonist (IL-1Ra) on the synovial membrane and joints of patients with rheumatoid arthritis. Arthritis Rheum. 1998;41:S138.

Dayer JM. Anti-interleukin-1 therapy in rheumatic diseases. Curr Opinion Rheum. 2001;13:170-176. Gabay C, Arend WP. Treatment of rheumatoid arthritis with IL-1 inhibitors. Springer Semin Immunopathol. 1998;20:229-246.

Granowitz EV, Porat R, Mier JW, et al. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine. 1992;4:353-360.

Jouvenne P, Vannier E, Dinarello CA, Miossec P. Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction. Arthritis Rheum. 1998;41:1083-1089.

Lebsack ME, Bloedow DC, Paul CC. Plasma levels of interleukin-1 receptor antagonist following subcutaneous infection in patients with rheumatoid arthritis. Clin Pharmacol Ther. 1992;51:192.

van den Berg WB. Uncoupling of inflammatory and destructive mechanisms in arthritis. Semin Arthritis Rheum. 2001;30:7-16.

Arbeiten zur Grundlagenforschung und sonstige Arbeiten:

Chomarat P, Vannier E, Dechanet J, et al. Balance of IL-1 receptor antagonist/IL-1B in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol. 1995; 1432-1439.

Deleuran BW, Shu CQ, Field M, et al. Localization of Interleukin-1 alpha, type 1 Interleukin-1 receptor and Interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol. 1992; 31:801-809.

Firestein GS, Boyle DL, Yu C, et al. Synovial Interleukin-1 receptor antagonist and Interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum. 1994; 37:644-652.

Hannum CH, Wilcox CJ, Arend WP, et al. Interleukin-1 receptor antagonist activity of a human Interleukin-1 inhibitor. Nature. 1990; 343:336-40.

Van Lent, PLEM, Fons, AJ, Van De Loo, AEM et al, Major role for Interleukin-1 but not for tumor necrosis factor in early cartilage damage in immune complex in mice. J Rheumatol. 1995; 22:2250-2258